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Introduction 
The autonomic system and sympathetic activation appears integral in the pathogenesis of 
acute mountain sickness (AMS) at high altitude (HA), yet a link between heart rate variability 
(HRV) and AMS has not been convincingly shown. In this study we investigated the utility of 
the smartphone-derived HRV score to predict and diagnose AMS at HA. 
Methods 
Twenty one healthy adults were investigated at baseline at 1400m and over 10 days during a 
trek to 5140m. HRV was recorded using the ithleteTM HRV device. 
Results 
AMS occurred in 11 subjects (52.4%) at >2650m. HRV inversely correlated with 
AMS Scores (r=-0.26; 95% CI -0.38 to -0.13: p<0.001). HRV significantly fell at 3700m, 
4100m and 5140m versus low altitude. HRV scores were lower in those with both mild 
(69.7±14.0) and severe AMS (67.1±13.1) versus those without AMS (77.5±13.1; effect size 
n2=0.043: p=0.007). The HRV score was weakly predictive of severe AMS (AUC 0.74; 95% 
CI 0.58 to 0.89: p=0.006). The change (delta) in the HRV Score (compared with baseline at 
1400m) was a moderate diagnostic marker of severe AMS (AUC 0.80; 95% CI 0.70 to 0.90; 
p=0.0004). A fall in the HRV score of >5 had a sensitivity of 83% and specificity of 60% to 
identify severe AMS (likelihood ratio 1.9). Baseline HRV at 1400m was not predictive of 
either AMS at higher altitudes. 
Conclusions 
The ithlete HRV score can be used to help in the identification of severe AMS, however a 
baseline score is not predictive of future AMS development at HA 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
High altitude (HA) illness consists of Acute Mountain Sickness (AMS), which is usually a self- 
limiting collection of symptoms including headache and lethargy, which can lead to? HA 
Cerebral Edema (HACE) and HA Pulmonary Edema (HAPE). HACE and HAPE are life-
threatening.1The incidence of AMS is dependent on a number of factors which include 
individual susceptibility, the speed of ascent and altitude attained.2  It is known to affect >50% 
of persons at ascending to an altitude of 5000m.1-4 
 
The mechanism of AMS development is highly complex and is still not fully understood.1 HA-
related hypoxia and changing homeostasis triggers a number of well-established physiological 
responses which include the adrenal medullary release of epinephrine and an increase in whole 
body and tissue specific sympathetic nerve activity.5 This leads to an increase in metabolic, 
heart and respiratory rate and changes in cerebral blood flow, that act to counteract the effects 
of hypobaric hypoxia.5-7 There is accumulating evidence to suggest that the autonomic system 
and alterations in the sympathetic/parasympathetic balance may play an important pathogenic 
role in the development of AMS and its susceptibility.7-11  
 
Heart rate variability (HRV) represents an increasingly utilised, yet non- invasive method of 
assessing autonomic function. HRV is quantified by measuring changes in cardiac beat-to-beat 
(R-R) intervals which are under continuous autonomic control.12 Conditions that are known to 
affect the sympathetic/parasympathetic balance such as inter-current illness, cardiovascular 
disease, physical overtraining ande mental stress have been shown to lead to a reduction in 
HRV.13-15 Changes in HRV have been demonstrated on ascent to HA and typified by an 
increase in measures of sympathetic and a decrease in parasympathetic activity.16,17 However, 
a link between alterations in HRV and AMS development at HA has not been convincingly 
shown.3,18-21 
 
Traditional methods of HRV measurement have required relatively large and expensive 
equipment with a need for at least five minutes of electrocardiographic (ECG) recording.22 The 
ithelte™ (HRV Fit Ltd, Southampton, UK) system is a recently available method of non-
invasive HRV assessment from only 55 seconds of recording obtained via a chest strap or finger 
sensor linked to a mobile smartphone. The ithelte™ generates an intuitive 1-100 HRV score 
which is a logarithmic adaptation of the root mean square of successive R-R intervals 
(RMSSD) provided by traditional HRV devices.23 It has been shown that the RMSDD, can be 
derived from shorter recording times and is less prone to the effects of respiration, which is 
  
advantgeous for the HA environment where hypoxia and hyperventilation is typical.24-26 The 
ithlete HRV score has been shown to provide good to excellent agreement with the RMSSD 
obtained from a standard five minute electrocardiographic recording at sea level and more 
recently at HA.25,27  
 
The aim of this study was to investigate, for the first time, the practical use of the ithelte™ 
HRV monitor as a way of monitoring acclimatisation to HA and the onset of AMS. 
 
METHODS 
Subjects 
Healthy British Military service personnel aged >18years were included. Health status was 
confirmed following a detailed baseline health questionnaire. All subjects had to be in date 
with their fitness assessments including the military fitness standard for a 1.5 mile run. Key 
exclusion criteria included subjects with any history of cardiac arrhythmias or need for either 
rate or rhythm controlling medications. All subjects lived at low altitude and none had prior 
exposure to >1400m terrestrial altitude in the four weeks prior to this study. 
Data collection took place during a trek to Dhaulagiri base camp (western Nepal). Subjects 
were all part of the British Services Dhaulagiri Medical Research Expedition. After arriving at 
Kathmandu at 1400m, the subjects travelled by road to 890m, then 2650m before commencing 
the ascent on foot to 5140m (over Dhamphus Pass, 5240m) over 10 days (figure 1). 
 
Recording of Heart Rate variability (HRV) 
HRV was recorded at approximately 0700 each morning using a finger sensor and linked 
smartphone via the ithlete™ app (HRV Fit Ltd. Southampton, UK) as previously described and 
validated.25,27 All participants were studied post micturition but prior to breakfast or caffeine. 
All subjects were seated, wearing warm clothing in either a tent or building. All subjects were 
encouraged to rest for at least five minutes before the HRV recordings were obtained. The 
ithelte™ acquires a 55 second recording with visual breathing prompts to regulate the rate of 
both inspiration and expiration in order to standardise the HRV measurements. The ithlete™ 
modifies the acquired RMSSD by taking the natural log transformation and multiplying by 
twenty (lnRMSSD × 20) to provide a more interpretable HRV score for the user on a ∼100 
point scale.23 It has a patented algorithm for the exclusion of both artifacts and ectopic beats 
whereby R-R (P-P) intervals of <500ms or >2000ms are excluded as are abnormal adjacent R-
R intervals whose difference significantly exceeds the mean R-R interval.28  
 
Acute mountain sickness (AMS) scores 
Measurement of AMS was undertaken at the same time that HRV assessments were performed 
using the Lake Louis Scoring System (LLS).29,30 A total score of >3 in the presence of headache 
was used to diagnose AMS and a score >5was considered consistent with severe AMS.29-31  
 
Physiological measurements 
Oxygen saturations (SpO2) and heart rate were measured using a Nonin Onyx (Nonin Medical 
Inc, Plymouth, Minnesota) pulse oximeter just prior to the assessment of HRV.  
 
Ethics 
The study was approved by the Ministry of Defence Research Ethics Committee and complied 
with the standards set in the Declaration of Helsinki. All subjects gave written informed 
consent. 
 
Statistical analysis 
  
Statistical calculations and figures were performed using GraphPad Instat and GraphPad Prism 
version 4.00 for Windows. Normality of continuous data was assessed following inspection 
and the Kolmogorov-Smirnov statistic. All continuous data are presented as the mean ± 
standard deviation. Independent two group comparisons of continuous data were analysed 
using an unpaired t test or Man Whitney test for parametric and non-parametric data 
respectively. Comparisons of continuous data from >3 groups of parametric and on parametric 
data were performed using a one-way ANOVA or Kruskal-Wallis test respectively. The effect 
size (n) for any potential changes in HRV with HA was also calculated as the sum of squares 
for between-treatment effects divided by the total sum of squares. Correlation analyses were 
performed using Pearson Correlation and Spearman’s rank correlation with 95% confidence 
intervals depending on data normality. Receiver operating characteristic (ROC) curves were 
constructed to assess the sensitivity and specificity of the ithlete™ and the area under the curve 
(AUC) for the HRV score to accurately identify subjects with AMS was determined. A p value 
of <0.05 was considered significant for all comparisons.  
 
 
 
RESULTS 
Twenty one subjects (20 men, 1 woman) aged 36.2±6.9 (years were studied over their first 13 
days in Nepal (table 1). Seventeen subjects reached 5140m on day 11, two on day 13 and two 
beyond the study period. There was a significant fall in SpO2 and increase in resting heart rate 
with gains in HA (Table 2). There was also an overall increase in LLS at HA (table 2) compared 
with the values at 890m. Successful ithleteTM recordings were possible in 93% of cases. AMS 
occurred in 11 subjects (52.4%) and all at an altitude of >2650m. There was a weak but 
significant correlation between HRV score and SpO2 r=0.16; 95% CI 0.02 – 0.29: p=0.02). 
HRV inversely correlated with LLS Scores (r=-0.26; -0.38 to -0.13: p<0.001). There was a 
moderate inverse correlation between the HRV score and heart rate (r=-0.41; -0.52 to 0.30: 
p<0.0001). 
 
HRV and acute Mountain Sickness 
There was a non-significant trend to reducing HRV score with increasing HA (n2 0.042; 
p=0.09) (table 2 and figure 2). However, this fall was significant at 3700m, 4100m and 5140m 
versus 890m. The HRV score fell with increasing AMS Scores (ANOVA n2=0.043; p=0.007) 
(figure 3), but this difference was only significant on post-test between those with a LLS of 0 
versus those with a LLS >5. HRV scores were significantly lower in those with AMS (mild 
and severe combined) 67.9±13.1 vs those without AMS 77.5±13.1 (p=0.002). HRV scores 
significantly fell from 77.5±13.1 for those with no AMS to 69.7±14.0 with mild AMS and 
67.1±13.1 with severe AMS (p=0.007, figure 4), however the difference was only significant 
between those without AMS and those with severe (not mild) AMS on post-test.  
 
The HRV score was very marginally better at distinguishing severe AMS versus those without 
severe AMS (ROC curve 0.74; 95% CI 0.58 to 0.89: p=0.006) than differentiating all AMS 
(mild and severe combined) from no AMS (area under the curve [AUC] 0.71: 95% CI 0.58 to 
0.84; p=0.002) (figure 5). An HRV score of <76 had a sensitivity of 83% and a specificity of 
53% for the correct identification of severe AMS at a likelihood ration of 1.80 (figure 5). 
However, the change (delta) in the ithlete™ HRV Score (compared with baseline at 1400m) 
was a better predictor of severe AMS (AUC 0.80; 95% CI 0.70 to 0.90; p=0.0004) (figure 6). 
A fall in the HRV score of >6 points compared had a sensitivity of 83% and specificity of 60% 
to identify severe AMS (likelihood ration 1.9) (figure 6). There was no difference in the HRV 
  
scores at 1400m between those who did or did not develop severe or any AMS at higher 
altitudes. 
 
DISCUSSION 
This is the first study, to the author’s knowledge, to investigate the link between AMS and 
HRV at HA to 5140m using a portable smart phone HRV device (ithleteTM). The ithleteTM HRV 
Score inversely correlated with the LLS but was a relatively weak discriminator for the 
identification of AMS and its severity. However, a fall in the HRV score, at HA versus baseline, 
of >6 versus baseline was a moderate albeit non-specific marker of severe AMS.  
 
There is an increasing body of research that has shown that HA exposure leads to a reduction 
in HRV. This is thought to relate to a significant increase in sympathetic and a decrease in 
parasympathetic tone.17,18,22 With acclimatization there appears to be progressive shift toward 
a higher parasympathetic tone.31 Much less is known about the link between HRV and AMS. 
There is data to suggest that changes in HRV are linked to the AMS susceptibility and 
development.19,22 but also data to the contrary challenging refuting this the link.20,21 This 
conflicting data may be partly explained by the marked differences in the design, ascent profile 
and the methods of HRV recording across the studies. Karinen et al studied 36 climbers on four 
different expeditions and three differing ascents. The authors found that those with a lower 
HRV (RMSSD2min and HF [high frequency] 2min from a five minute HRV recording) at 2400m 
predicted those who later developed AMS at moderate altitudes (3000-4300m).22 Huang et al 
study 32 patients over a progressive HA trek to 3440m. They noted that those with both (high 
frequency) HF% < 20% (suggesting reduced parasympathetic tone) and low frequency: high 
frequency (LF:HF) ratio > 1.3 (increased sympathetic balance) measured at 1317 m had an 
odds ratios of 7.00 (p = 0.047) for the subsequent development of develop AMS at 3440m 
(Huang 2013).19 The authors did not report data on the RMSSD. In our study whilst we did 
observe significantly lower ithleteTM HRV (RMSSD) scores in those with AMS and more 
severe AMS, lower altitude HRV scores failed to predict AMS development at HA. 
Furthermore the effect size for change in HRV with worsening AMS severity was modest. 
 
One of the major additional confounders in all of these studies examining the relationship of 
HRV to symptom of AMS has been in the definition of AMS itself. The diagnosis of AMS is 
made using a self-reported questionnaire based assessment, most notably the LLS and is highly 
subjective and therefore likely to be influenced by a subjects’ expectations or aspirations and 
it can be a relatively poor predictor of illness.33,34 For example, in a previous study of 248 
healthy adults travelling to 3200m Bartsch has noted that only 61% of the mountaineers 
reporting a LLS>5 actually said they felt ill.35 Hence, a more reproducible and objective 
measure of HA- related illness would be welcome. The rational for using HRV to improve the 
detection of AMS is strong. Whilst the underlying pathophysiology of AMS is still poorly 
understood current evidence suggests that it involves vasogenic cerebral oedema secondary to 
hypoxia-induced sympathetic activation.1 The normal physiological diuresis at HA, which acts 
to reduce plasma volume and increase in haematocrit (to improve tissue oxygenation) , is also 
affected leading to a reduced water clearance and a positive net water balance.36 Changes in 
plasma volume which is integral to the HA acclimatisation and AMS development are strongly 
influenced by alterations in parasympathetic tone.37 HRV is also heavily afeected by a number 
of other autonomic stressors such as fitness levels, physical fatigue, cold and exertion which 
important factors at HA and are known to be contributory factors to AMS development and 
progression.38  
 
  
One of the greatest clinical applications of the ithleteTM and other HRV measures is in the 
detection of overtraining which shares many features in common with AMS. Hence further 
studies examining the utility of HRV to monitor recovery from exercise at HA and to tailor 
individuals’ acclimatisation, rather than relying on guidelines such as 300m ascent per day, 
would be welcome. The ithleteTM is currently marketed with a visual display of other domains 
such as sleep, fatigue, irritability and muscle soreness which could be potentially adapted to 
give a scale related to the LLS and is an area worthy of further research.  
 
This study has a number of limitations and strengths that need to be acknowledged. The 
ambient temperature varied throughout the study and the HRV measurements were performed 
in tents above 1400m. It is well known that change in both environment and temperature can 
influence HRV and due to the nature of this study it was not possible to adjust for these 
factors.38 In this study we used a finger probe rather than a blue tooth chest strap sensor to 
acquire heart beat data and successful data recording was not possible in 7% which could have 
influenced the findings. The ithleteTM only provides a single measure of HRV from a very short 
recording time. Hence, we do not know whether our findings would be different if another 
HRV platform and a five-minute recording period with a wider array of HRV data outputs 
include frequency domain analyses were used. The ithleteTM HRV score is related the RMSSD 
and is considered a marker of relative parasympathetic activity and does not assess sympathetic 
tone or the sympathetic/parasympathetic balance provided by more sophisticated devices. 
However, the aim of this study was to assess the utility of a simple, inexpensive, portable and 
user friendly deice that is widely available to potentially predict HA related illness and hence 
maximising the clinical impact of a potentially strongly positive finding. The key strengths of 
this study was that all subjects underwent the same exercise, diet and acclimatisation protocol 
and the altitude achieved was significant and greater than the majority of published HRV 
studies at HA. 
 
In summary this is the first paper to show a practical application of a simple measure of HRV 
to provide an objective measure of severe AMS. A fall in the ithleteTM HRV score of >6 
points from baseline had moderate precision for the detection of severe AMS.  
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Figure 1 Ascent profile 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Changes in ithleteTM Heart Rate Variability Score with increases in altitude 
 
 
 
 
  
 
 
 
 
 
Figure 3 Changes in Heart Rate Variability with Acute Mountain Sickness Scores (LLS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4 Acute Mountain Sickness Severity and ithleteTM Heart Rate Variability Scores 
 
 
  
 
Figure 5 Receiver operating characteristic (ROC) Curve for Heart Rate Variability score for 
Detection of severe Acute Mountain Sickness 
 
 
 
 
 
 
Figure 6 Receiver operating characteristic (ROC) Curve for change in Heart Rate Variability 
score and identification of severe Acute Mountain Sickness 
